Altium Capital Management LLC Reduces Stock Position in Perspective Therapeutics, Inc. (NYSE:CATX)

Altium Capital Management LLC decreased its holdings in shares of Perspective Therapeutics, Inc. (NYSE:CATX - Free Report) by 68.2% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 92,224 shares of the company's stock after selling 197,776 shares during the period. Altium Capital Management LLC owned approximately 0.14% of Perspective Therapeutics worth $294,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Y Intercept Hong Kong Ltd purchased a new stake in Perspective Therapeutics during the fourth quarter valued at about $33,000. Aigen Investment Management LP bought a new position in shares of Perspective Therapeutics during the 4th quarter valued at about $34,000. National Bank of Canada FI raised its holdings in shares of Perspective Therapeutics by 549,900.0% during the 4th quarter. National Bank of Canada FI now owns 11,000 shares of the company's stock valued at $35,000 after buying an additional 10,998 shares in the last quarter. Vontobel Holding Ltd. bought a new stake in Perspective Therapeutics in the 4th quarter worth approximately $51,000. Finally, Trueblood Wealth Management LLC boosted its stake in Perspective Therapeutics by 37.0% in the fourth quarter. Trueblood Wealth Management LLC now owns 22,236 shares of the company's stock worth $71,000 after buying an additional 6,000 shares in the last quarter. 54.66% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Perspective Therapeutics

In other news, CEO Johan M. Spoor acquired 22,026 shares of Perspective Therapeutics stock in a transaction on Friday, March 28th. The stock was acquired at an average cost of $2.24 per share, for a total transaction of $49,338.24. Following the purchase, the chief executive officer now owns 59,383 shares in the company, valued at $133,017.92. This trade represents a 58.96 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Juan Graham bought 33,333 shares of the firm's stock in a transaction on Friday, March 28th. The stock was purchased at an average cost of $2.25 per share, with a total value of $74,999.25. Following the completion of the acquisition, the chief financial officer now directly owns 35,354 shares of the company's stock, valued at approximately $79,546.50. The trade was a 1,649.33 % increase in their position. The disclosure for this purchase can be found here. Insiders have purchased a total of 115,696 shares of company stock valued at $256,344 in the last ninety days. 3.52% of the stock is currently owned by corporate insiders.

Perspective Therapeutics Trading Up 7.0 %

Shares of NYSE:CATX traded up $0.15 on Wednesday, hitting $2.29. The company had a trading volume of 435,353 shares, compared to its average volume of 1,020,744. The firm's 50-day simple moving average is $2.35 and its two-hundred day simple moving average is $4.90. Perspective Therapeutics, Inc. has a 1 year low of $1.60 and a 1 year high of $19.05.

Analyst Upgrades and Downgrades

CATX has been the subject of a number of research reports. Royal Bank of Canada cut their price objective on shares of Perspective Therapeutics from $16.00 to $15.00 and set an "outperform" rating for the company in a research note on Thursday, March 27th. Truist Financial dropped their target price on Perspective Therapeutics from $21.00 to $10.00 and set a "buy" rating for the company in a report on Monday, April 7th. Wedbush reaffirmed an "outperform" rating and issued a $11.00 price target on shares of Perspective Therapeutics in a research note on Wednesday, March 26th. Lifesci Capital upgraded shares of Perspective Therapeutics to a "strong-buy" rating in a report on Thursday, March 6th. Finally, Brookline Capital Management upgraded shares of Perspective Therapeutics to a "strong-buy" rating in a report on Monday, March 10th. One research analyst has rated the stock with a hold rating, seven have given a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of "Buy" and an average target price of $12.75.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.